Abstract
Associations between blood urate levels, blood pressure (BP), and kidney function have previously been reported in observational studies. However, causal inference between these three traits is challenging due to potentially bidirectional relationships. We applied bidirectional univariable Mendelian randomization (UVMR) to assess the causal relationships between urate levels, BP, and kidney function, proxied by estimated glomerular filtration rate (eGFR), by using genetic associations from both UK Biobank and CKDGen. We performed multivariable MR (MVMR) to assess the independent effects of urate and BP on eGFR. Effect estimates are presented as standard deviation (SD) change in outcome per SD increase in exposure [95% confidence interval]. UVMR analysis suggested a bidirectional causal effect between urate and eGFR (urate on log(eGFR): beta=-0.10 [-0.22 to 0.02]; log(eGFR) on urate: beta=-0.11 [-0.17 to -0.04]). There was strong evidence of bidirectional causal effects between urate and SBP (urate on SBP: beta=0.08 [0.04 to 0.11]; SBP on urate: beta=0.13 [0.08 to 0.18]). Similar bidirectional causal effects were identified between urate and DBP (urate on DBP: beta=0.09 [0.05 to 0.14]; DBP on urate: beta=0.13 [0.08 to 0.18]). However, there was weak evidence of a causal effect between BP and eGFR. MVMR results suggested the causal effect of urate on eGFR was independent of BP. Our results provide evidence for bidirectional causal effects between urate and both eGFR and BP, suggesting urate control as a potential intervention to reduce BP and decline in kidney function in the general population, but little evidence of a causal relationship between BP and eGFR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4 and MC_UU_00032/03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This research has been conducted with the UK Biobank Resource under application number 15825.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The summary-level data from CKDGen are publicly available (http://ckdgen.imbi.uni-freiburg.de/) and OpenGWAS (https://gwas.mrcieu.ac.uk/). The UK Biobank individual-level data can be accessed through an application (https://www.ukbiobank.ac.uk/).